Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 13/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707231 | 0.89 | ENPP3 (0.43) | ENPP3CA2CA9GAAKDR | |
| SCHEMBL15663527 | 0.88 | ENPP3 (0.46) | ENPP3GAAKDRPOLBMAPT | |
| SCHEMBL3703013 | 0.85 | AURKA (0.45) | ENPP3CA2CA9CA1KDR | |
| SCHEMBL15663303 | 0.84 | MAPT (0.44) | ENPP3CA2CA9GAATP53 | |
| SCHEMBL15663538 | 0.83 | KDR (0.38) | ENPP3KDRMAPTHPGD | |
| SCHEMBL15663740 | 0.81 | KDR (0.44) | ENPP3CA2CA9CA1GAA | |
| SCHEMBL3698986 | 0.79 | GAA (0.40) | ENPP3CA2CA9CA1GAA | |
| SCHEMBL3699414 | 0.78 | KDR (0.47) | ENPP3GAAKDRTP53POLB | |
| SCHEMBL15663410 | 0.77 | MAPT (0.45) | ENPP3CA9GAAKDRTP53 | |
| SCHEMBL3704302 | 0.74 | KDR (0.43) | ENPP3KDRMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | ENPP3 1630/4885CA2 1759/4885CA9 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.